07:00 , May 16, 2016 |  BC Week In Review  |  Clinical News

ITCA 650: Phase III data

Top-line data from the double-blind, international Phase III FREEDOM-CVO cardiovascular outcomes trial in >4000 Type II diabetics showed that once-daily 60 ug ITCA 650 plus standard of care (SOC) met the primary endpoint of non-inferiority...
07:00 , Aug 24, 2015 |  BC Week In Review  |  Clinical News

ITCA 650: Phase III data

Top-line data from the double-blind, international Phase III FREEDOM-2 trial in 535 Type II diabetics with an HbA1c of 7.5-10.5% showed that once-daily 60 ug ITCA 650 met the primary endpoint of reducing HbA1c from...
07:00 , Jun 15, 2015 |  BC Week In Review  |  Clinical News

ITCA 650: Additional Phase III data

Additional data from the double-blind, U.S. Phase III FREEDOM-1 trial in 460 Type II diabetics with an HbA1c of 7.5-10% not controlled on 0-3 oral diabetes drugs showed that once-daily ITCA 650 reduced mean HbA1c...
07:00 , May 11, 2015 |  BC Week In Review  |  Clinical News

Ionsys fentanyl iontophoretic transdermal system regulatory update

FDA approved an sNDA from The Medicines Co. for Ionsys fentanyl iontophoretic transdermal system for the short-term management of acute postoperative pain in adults requiring opioid analgesia during hospitalization. The company plans to launch the...
07:00 , Oct 6, 2014 |  BC Week In Review  |  Clinical News

ITCA 650: Additional Phase III data

Additional data from the open-label, U.S. Phase III FREEDOM-1 HBL trial in 59 Type II diabetics with an HbA1c of >10% and <=12% not controlled on 0-3 oral diabetes drugs showed that ITCA 650 led...
07:00 , Oct 6, 2014 |  BC Week In Review  |  Clinical News

ITCA 650: Phase III data

The double-blind, U.S. Phase III FREEDOM-1 trial in 460 Type II diabetics with an HbA1c of 7.5-10% not controlled on 0-3 oral diabetes drugs showed that once-daily 40 and 60 Ug doses of ITCA 650...
07:00 , Jun 23, 2014 |  BC Week In Review  |  Clinical News

ITCA 650: Interim Phase III data

Interim data from the open-label, U.S. Phase III FREEDOM 1 HBL trial in 60 Type II diabetics with an HbA1c of >10% to <=12% that is not controlled on 0-3 oral diabetes drugs showed that...
07:00 , Apr 7, 2014 |  BioCentury  |  Finance

All in for Type II

A potentially de-risked product for a giant indication was enough to get investors in diabetes company Intarcia Therapeutics Inc. to pony up $200 million in the largest venture round in the past five quarters. The...
00:11 , Apr 2, 2014 |  BC Extra  |  Financial News

Intarcia raises $200 million

Intarcia Therapeutics Inc. (Boston, Mass.) raised $200 million in a series DD round led by new investor RA Capital. New investors Franklin Templeton LLC; Fred Alger Management; and Quilvest also participated along with existing investors...
07:00 , Mar 24, 2014 |  BioCentury  |  Strategy

A Remembrance: The quintessential serial entrepreneur

Very few of us will live as long, invent as much, or improve as many lives as Alejandro Zaffaroni. Alex, who was 91 when he passed away this month, already was an eminence grise in...